跳至主要内容
临床试验/NCT00229112
NCT00229112已完成3 期

A Prospective, Multicenter, Double-Blind With In-House Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability, of Ertapenem Versus Piperacillin/Tazobactam in the Treatment of Diabetic Foot Infections in Adults.

Merck Sharp & Dohme LLC0 个研究点目标入组 400 人开始时间: 2001年4月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
400
主要终点
Clinical Cure/Improvement at discontinuation of IV antibiotic therapy.

研究概览

简要总结

This study will compare the efficacy, safety and tolerability of intravenous ertapenem versus another intravenous antibiotic in the treatment of moderate to severe diabetic foot infections.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Type 1 or 2 Diabetes Mellitus treated with diet or medication
  • Clinically or microbiologically documented foot infection below the knee
  • Osteomyelitic bone must be removed within 48 hours of study entry

排除标准

  • Uncomplicated skin infections
  • Infected burn wounds
  • Necrotizing fascitis
  • Wounds with gangrene that cannot be removed with debridement
  • Infections of prosthetic materials
  • Foreign materials that can not be removed by surgical debridement
  • Patients with another antibiotic 3 days prior to enrollment without evidence of treatment failure and presence of a positive culture
  • Insufficient blood flow to the limb requiring a revascularization procedure

结局指标

主要结局

Clinical Cure/Improvement at discontinuation of IV antibiotic therapy.

次要结局

  • Clinical Cure: 1. Day 5 of IV antibiotic therapy; 2.10 days after completion of all antibiotic therapy.

研究者

申办方类型
Industry
责任方
Sponsor

相似试验